174 related articles for article (PubMed ID: 24064969)
1. Treatment costs associated with interventional cancer clinical trials conducted at a single UK institution over 2 years (2009-2010).
Liniker E; Harrison M; Weaver JM; Agrawal N; Chhabra A; Kingshott V; Bailey S; Eisen TG; Corrie PG
Br J Cancer; 2013 Oct; 109(8):2051-7. PubMed ID: 24064969
[TBL] [Abstract][Full Text] [Related]
2. Cancer Clinical Trials: Treatment Costs Associated With a Spanish National Health System Institution.
Capdevila F; Vera R; Ochoa P; Galbete A; Sanchez-Iriso E
Ther Innov Regul Sci; 2019 Sep; 53(5):641-647. PubMed ID: 30428709
[TBL] [Abstract][Full Text] [Related]
3. Measuring the incremental cost of clinical cancer research.
Goldman DP; Schoenbaum ML; Potosky AL; Weeks JC; Berry SH; Escarce JJ; Weidmer BA; Kilgore ML; Wagle N; Adams JL; Figlin RA; Lewis JH; Cohen J; Kaplan R; McCabe M
J Clin Oncol; 2001 Jan; 19(1):105-10. PubMed ID: 11134202
[TBL] [Abstract][Full Text] [Related]
4. Incremental costs of enrolling cancer patients in clinical trials: a population-based study.
Wagner JL; Alberts SR; Sloan JA; Cha S; Killian J; O'Connell MJ; Van Grevenhof P; Lindman J; Chute CG
J Natl Cancer Inst; 1999 May; 91(10):847-53. PubMed ID: 10340904
[TBL] [Abstract][Full Text] [Related]
5. The costs of conducting clinical research.
Emanuel EJ; Schnipper LE; Kamin DY; Levinson J; Lichter AS
J Clin Oncol; 2003 Nov; 21(22):4145-50. PubMed ID: 14559889
[TBL] [Abstract][Full Text] [Related]
6. Incremental treatment costs in national cancer institute-sponsored clinical trials.
Goldman DP; Berry SH; McCabe MS; Kilgore ML; Potosky AL; Schoenbaum ML; Schonlau M; Weeks JC; Kaplan R; Escarce JJ
JAMA; 2003 Jun; 289(22):2970-7. PubMed ID: 12799405
[TBL] [Abstract][Full Text] [Related]
7. An estimate of the cost of conducting phase II trials in lung cancer.
Evans WK; Dahrouge S; Stapleton J; Quinn C; Pollock D; Waterfield B; Lister D; Hansel F; Smith A
Lung Cancer; 2000 May; 28(2):85-95. PubMed ID: 10717326
[TBL] [Abstract][Full Text] [Related]
8. Clinical trials: are they a good buy?
Bennett CL; Adams JR; Knox KS; Kelahan AM; Silver SM; Bailes JS
J Clin Oncol; 2001 Dec; 19(23):4330-9. PubMed ID: 11731516
[TBL] [Abstract][Full Text] [Related]
9. Free drugs in clinical trials and their potential cost saving impact on the National Health Service: a retrospective cost analysis in Italy.
Grossi F; Genova C; Gaitan ND; Dal Bello MG; Rijavec E; Barletta G; Sini C; Donato C; Beltramini S; Pronzato P; Porcile G; Boccardo F; Walzer S
Lung Cancer; 2013 Aug; 81(2):236-40. PubMed ID: 23648072
[TBL] [Abstract][Full Text] [Related]
10. Costs of clinical trials with anticancer biological agents in an Oncologic Italian Cancer Center using the activity-based costing methodology.
Pascarella G; Capasso A; Nardone A; Triassi M; Pignata S; Arenare L; Ascierto P; Curvietto M; Maiolino P; D'Aniello R; Montanino A; Laudato F; De Feo G; Botti G; Perrone F; Petrillo A; Cavalcanti E; Lastoria S; Maurea N; Morabito A
PLoS One; 2019; 14(1):e0210330. PubMed ID: 30620767
[TBL] [Abstract][Full Text] [Related]
11. Cost-benefit assessment of using electronic health records data for clinical research versus current practices: Contribution of the Electronic Health Records for Clinical Research (EHR4CR) European Project.
Beresniak A; Schmidt A; Proeve J; Bolanos E; Patel N; Ammour N; Sundgren M; Ericson M; Karakoyun T; Coorevits P; Kalra D; De Moor G; Dupont D
Contemp Clin Trials; 2016 Jan; 46():85-91. PubMed ID: 26600286
[TBL] [Abstract][Full Text] [Related]
12. Drug cost savings in phase III hematological oncology clinical trials in a university hospital.
Herledan C; Ranchon F; Schwiertz V; Baudouin A; Karlin L; Ghesquières H; Salles G; Rioufol C
Hematol Oncol; 2020 Oct; 38(4):576-583. PubMed ID: 32469095
[TBL] [Abstract][Full Text] [Related]
13. The influence of industry sponsorship on the reporting of subgroup analyses within phase III randomised controlled trials in gastrointestinal oncology.
Barton S; Peckitt C; Sclafani F; Cunningham D; Chau I
Eur J Cancer; 2015 Dec; 51(18):2732-9. PubMed ID: 26608121
[TBL] [Abstract][Full Text] [Related]
14. Retrospective pharmaceutical financial benefits and cost avoidance analysis of clinical trial participation in the Australian haematology setting.
Truong K; Kwan YL; Nigro L; Huseincehajic A; Trotman J
Intern Med J; 2019 Sep; 49(9):1092-1098. PubMed ID: 30907047
[TBL] [Abstract][Full Text] [Related]
15. The role of clinical trials in the sustainability of the Italian national health service cancer drug expenditure.
Gasperoni L; Cafaro A; Ferretti E; Di Iorio V; Nanni O; Masini C
Eur J Hosp Pharm; 2023 Mar; 30(2):96-100. PubMed ID: 35577545
[TBL] [Abstract][Full Text] [Related]
16. Association of Industry and Academic Sponsorship With Negative Phase 3 Oncology Trials and Reported Outcomes on Participant Survival: A Pooled Analysis.
Addeo A; Weiss GJ; Gyawali B
JAMA Netw Open; 2019 May; 2(5):e193684. PubMed ID: 31074821
[TBL] [Abstract][Full Text] [Related]
17. Efaproxiral: GSJ 61, JP 4, KDD 86, RS 4, RSR 13.
Drugs R D; 2005; 6(3):178-85. PubMed ID: 15869322
[TBL] [Abstract][Full Text] [Related]
18. Repaglinide : a pharmacoeconomic review of its use in type 2 diabetes mellitus.
Plosker GL; Figgitt DP
Pharmacoeconomics; 2004; 22(6):389-411. PubMed ID: 15099124
[TBL] [Abstract][Full Text] [Related]
19. Erlotinib: CP 358774, NSC 718781, OSI 774, R 1415.
Adis International Ltd
Drugs R D; 2003; 4(4):243-8. PubMed ID: 12848590
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
